|
04 Mar 2020 |
MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours
|
|
04 Mar 2020 |
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
|
|
04 Mar 2020 |
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
|
|
04 Mar 2020 |
Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents
|
|
03 Mar 2020 |
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation
|
|
26 Feb 2020 |
Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors
|
|
21 Feb 2020 |
VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
|
|
21 Feb 2020 |
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
|
|
21 Feb 2020 |
Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders
|
|
21 Feb 2020 |
First Patient Dosed With Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer With Liver Metastases
|
|
20 Feb 2020 |
Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease
|
|
20 Feb 2020 |
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
|
|
20 Feb 2020 |
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
|
|
19 Feb 2020 |
Gene Therapy Phase 3 Trial for Painful Diabetic Peripheral Neuropathy Using Engensis (or VM202), a plasmid DNA engineered to express human HGF proteins by simple intramuscular injections
|
|
19 Feb 2020 |
Cellectis and Servier Expand Collaboration on UCART19 Products
|
|
18 Feb 2020 |
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
|
|
18 Feb 2020 |
Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy
|
|
16 Feb 2020 |
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
|
|
13 Feb 2020 |
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
|
|
13 Feb 2020 |
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium
|
|
13 Feb 2020 |
Marker Therapeutics Announces Update to its Clinical Program in AML
|
|
12 Feb 2020 |
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
|
|
11 Feb 2020 |
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
|
|
11 Feb 2020 |
AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
|
|
11 Feb 2020 |
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
|
